Elektrofi, Takeda partner to advance plasma protein therapeutics

By The Science Advisory Board staff writers

September 21, 2020 -- Biotechnology firm Elektrofi and Takeda Pharmaceuticals have partnered to advance high-concentration, low-viscosity protein therapeutics.

Under the evaluation agreement, Takeda will evaluate Elektrofi's microparticle-based formulation technology, Elektroject. Elektroject uses proprietary technology to generate highly concentrated, small-volume injections of monoclonal antibodies, therapeutic proteins, and other biologics.

Takeda will investigate the storage stability and properties of microparticles created by Elektroject, as well as the stability and formulations with high concentrations of a target protein. Terms of the agreement were not disclosed.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.